Quercetin Modulates Hippo Pathway to Protect Cataract Lenses

Study Background and Research Question

Cataracts remain the leading cause of irreversible blindness worldwide, accounting for over 51% of global cases and affecting approximately 94 million people as of 2020 (source: paper). The pathological hallmark—lens opacification—stems from cumulative oxidative stress and dysregulated lens epithelial cell (LEC) behavior, with prevalence sharply increasing with age. Although surgical intervention is highly effective, it is costly and often inaccessible in resource-limited settings. This has driven the search for pharmacological or natural compound-based strategies for cataract prevention or delay (source: paper).

Traditional Chinese medicine (TCM) has garnered substantial interest due to its multi-pathway targeting potential, with herbal compounds like quercetin showing antioxidant and anti-inflammatory effects. However, the molecular mechanisms by which these agents exert lens-protective actions are incompletely understood. Recent genetic and biochemical studies implicate the Hippo pathway—a regulator of proliferation, apoptosis, and tissue homeostasis—in cataractogenesis. Aberrant Hippo signaling, particularly involving MST1/2, YAP, and TAZ, is associated with LEC dysfunction, increased ferroptosis, and enhanced oxidative damage. The central research question of the reference study is: Does quercetin ameliorate cataract pathology via modulation of the Hippo signaling pathway, and what are the consequences for lens epithelial cell survival and proliferation?

Key Innovation from the Reference Study

This study offers the first comprehensive demonstration that quercetin's lens-protective effects in cataract models are mechanistically linked to the suppression of Hippo pathway activation. By combining network-pharmacology analyses, in vivo UVB-induced cataract mouse models, and in vitro oxidative injury assays, the authors establish quercetin as a top Hippo-associated natural compound. The innovative aspect lies in the systematic correlation of quercetin's biochemical actions—reduction of oxidative stress and promotion of epithelial cell survival—with direct modulation of Hippo pathway components. Importantly, the study shows that re-activation of Hippo signaling with α-hederin reverses these beneficial effects, underscoring the pathway's centrality in lens protection (source: paper).

Methods and Experimental Design Insights

The investigators employed a multi-tiered approach:

• Network-pharmacology analysis: Used to identify cataract-related molecular targets and enriched signaling pathways, with quercetin emerging as the top candidate compound linked to Hippo pathway modulation.
• In vivo studies: A UVB-induced cataract mouse model was developed. Mice were treated with quercetin, with or without the Hippo activator α-hederin. Assessments included lens opacity grading, histopathology, oxidative stress markers (malondialdehyde [MDA], glutathione [GSH], superoxide dismutase [SOD]), and expression of key Hippo and apoptosis/proliferation markers (p-MST1, p-YAP, TAZ, Ki-67, BCL-2, BAX, Cleaved Caspase-3).
• In vitro studies: Mouse LECs subjected to H₂O₂-induced oxidative injury were treated with quercetin ± α-hederin. Cell proliferation was measured via CCK-8 assay, while protein expression profiles were evaluated by western blotting.

This experimental design allowed direct comparison of quercetin's effects on both functional (opacity, cell proliferation) and molecular (pathway protein levels) endpoints in a controlled manner (source: paper).

Core Findings and Why They Matter

Network analysis revealed that the Hippo pathway is the most significantly enriched pathway in cataract-related gene sets, with quercetin showing the strongest overlap with Hippo targets. In vivo, quercetin administration reduced lens opacification and restored histological architecture. Quercetin normalized oxidative stress markers—lowering MDA and elevating GSH and SOD levels—indicative of improved redox homeostasis.

At the signaling level, quercetin treatment led to decreased phosphorylation of MST1 and YAP, as well as lower TAZ expression, consistent with Hippo pathway inactivation. This was accompanied by increased expression of the proliferation marker Ki-67 and anti-apoptotic BCL-2, with concurrent reductions in pro-apoptotic BAX and Cleaved Caspase-3. These molecular changes signal enhanced epithelial cell survival and reduced apoptosis (source: paper).

Reversal experiments with α-hederin, a Hippo pathway activator, counteracted quercetin’s protective effects both in vivo and in vitro, restoring Hippo pathway activity and increasing cell stress. In H₂O₂-injured LECs, quercetin promoted proliferation and suppressed Hippo signaling, again reversible by α-hederin. Collectively, these results establish a causal relationship between Hippo pathway suppression, quercetin administration, and lens protection.

These findings matter because they define a new actionable target—the Hippo pathway—for cataract pharmacotherapy and suggest that natural compounds like quercetin may be optimized for preventive or adjunctive non-surgical interventions.

Comparison with Existing Internal Articles

Most internal articles on Fasudil (HA-1077) HCl and the Rho/ROCK pathway focus on cellular proliferation inhibition, migration suppression, and apoptosis induction in cancer and hematological models (source: internal). The Rho/ROCK and Hippo pathways share overlapping regulatory roles in cell fate and cytoskeletal dynamics, and recent reviews have highlighted their crosstalk in disease contexts (source: internal). Like quercetin's effect on Hippo, ROCK inhibitors such as Fasudil (HA-1077) HCl demonstrate robust cell proliferation inhibition and cytoprotective actions, particularly in cancer, by blocking Rho/ROCK signaling (source: internal). Both approaches support the principle of targeting intracellular signaling networks to achieve disease-modifying outcomes. However, the reference study uniquely applies this paradigm to lens biology and cataract prevention, expanding the therapeutic landscape beyond oncology and hematological disorders.

Limitations and Transferability

Despite its strengths, the study is limited by its reliance on animal models and acute injury paradigms, which may not fully replicate human cataractogenesis. The in vitro LEC model, while informative, cannot recapitulate the complex microenvironment of the human lens. The precise off-target effects of quercetin and the long-term safety profile remain to be elucidated. Furthermore, while α-hederin serves as a pharmacological Hippo activator, the specificity of this intervention warrants further validation. Translation of these findings to clinical use will require additional preclinical studies and eventual human trials (source: paper).

Protocol Parameters

• UVB-induced cataract mouse model | 100 mJ/cm² UVB exposure | In vivo lens injury modeling | Mimics oxidative stress-related cataractogenesis | paper
• Quercetin dosing | 50 mg/kg, i.p., daily | In vivo | Dose selected for efficacy and safety in mouse models | paper
• Hippo pathway activation | α-Hederin, 10 mg/kg, i.p., daily | In vivo/in vitro | To selectively re-activate Hippo signaling for reversal studies | paper
• LEC oxidative injury | 200 μM H₂O₂, 24 h | In vitro | Induces oxidative stress for lens cell injury modeling | paper
• CCK-8 proliferation assay | Standard kit, 450 nm readout | In vitro LEC viability | Quantifies cell proliferation post-treatment | paper
• Western blot markers | p-MST1, p-YAP, TAZ, Ki-67, BCL-2, BAX, Cleaved Caspase-3 | In vivo/in vitro | To track Hippo activation and apoptosis/proliferation | paper
• Fasudil (HA-1077) HCl for ROCK pathway studies | 0.74 μM IC50; 100 mg/kg in vivo | Cancer/apoptosis/ROCK signaling research | Mechanistically distinct but relevant for pathway inhibition workflows | product_spec

Research Support Resources

For researchers investigating cell proliferation inhibition, cell migration suppression, or apoptosis induction in diverse disease models—including cancer and potentially ocular disorders—selective ROCK inhibitors such as Fasudil (HA-1077) HCl (SKU A5734) from APExBIO offer robust, well-characterized tools for dissecting Rho/ROCK pathway function (source: product_spec). While the present study focuses on Hippo pathway modulation in cataract, integration of ROCK pathway inhibition—leveraging agents like Fasudil—may further expand mechanistic insights or therapeutic options in related models. Full product specifications and storage recommendations can be found at the APExBIO website.